SCHEMBL6418375

SCHEMBL6418375

Fc1ccc(Nc2nc3nonc3nc2N/N=C\c2ccc(-c3ccc(Cl)cc3Cl)o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
KDM4E B2RXH2 7/20 0.52
GAA P10253 5/20 0.52
NPC1 O15118 4/20 0.52
NPSR1 Q6W5P4 4/20 0.52
POLB P06746 3/20 0.52
MCL1 Q07820 2/20 0.52
MAPK1 P28482 1/20 0.45
RAB9A P51151 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
BIRC5 O15392 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 4/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418378 1.00 MAPT (0.52) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6435673 0.87 MEN1 (0.48) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6505849 0.81 BIRC5 (0.53) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6505842 0.81 BIRC5 (0.53) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6413614 0.81 MAPT (0.46) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6413618 0.81 MAPT (0.46) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6433043 0.79 MEN1 (0.66) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6433034 0.79 MEN1 (0.66) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6503291 0.79 MET (0.52) MAPTKDM4EGAANPC1NPSR1
SCHEMBL6506319 0.79 MET (0.52) MAPTKDM4EGAANPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KDM4E 3277/4885GAA 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.